paclitaxel submicron particle (SOR007) / DFB Pharma, NanOlogy - LARVOL DELTA

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer (Businesswire) - '"Cutaneous metastases are extremely troublesome for the patient and oncologist alike as the lesions are a daily reminder of the underlying metastatic disease and there are few treatment options currently available,' said Mario Lacouture, MD...'In this Phase 1/2 clinical trial, SOR007 showed promising signs of preventing lesion progression and reducing lesion pain. Further clinical research is warranted to confirm these findings.'"

Media quote

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer (Businesswire) - P1/2 | N=23 | NCT03101358 | Sponsor: NanOlogy, LLC | "NanOlogy LLC...announced today that results from a clinical trial of topical submicron particle paclitaxel (SOR007) in cutaneous metastases of breast cancer (CMBOC) have been published in Breast Cancer Research and Treatment....SOR007 was well tolerated at all concentrations allowing the 2.0% concentration to continue to the dose expansion phase of the trial....At the 28-day and 56-day assessments, overall response rate was 16% (3/19) and 25% (2/8), respectively."

P1/2 data • Breast Cancer • Oncology